Drug or intervention
aldesleukin Clinical Trials
Studies that test aldesleukin, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 40Endocrine Tumors, Non-Small Cell Lung Cancer
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible.
- Conditions
- Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03412877
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 285 people
- Sponsor
- National Cancer Institute (NCI)
Malignancy, Hematologic, Neoplasms, Hematologic
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes.
- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer
- Trial name
- NCT06904066
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Renal Cell Cancer
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person.
- Conditions
- Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma
- Trial name
- NCT02830724
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Throat Cancer
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers.
- Conditions
- Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer
- Trial name
- NCT05686226
- Testing
- E7 TCR-T cells, Aldesleukin
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Christian Hinrichs
Gastric Cancer, Breast Cancer
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1.
- Conditions
- Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
- Trial name
- NCT05483491
- Testing
- KK-LC-1 TCR-T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Christian Hinrichs
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated…
- Conditions
- HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05639972
- Testing
- E7 TCR-T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Christian Hinrichs
Metastatic Melanoma, Advanced Locoregional Melanoma
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Background: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma.
- Conditions
- Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
- Trial name
- NCT05155033
- Testing
- Pembrolizumab, Aldesleukin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the…
- Conditions
- Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma
- Trial name
- NCT01174121
- Testing
- Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the…
- Conditions
- Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma
- Trial name
- NCT02133196
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory Multiple Myeloma
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the…
- Trial name
- NCT07681596
- Testing
- AZD4045, Daratumumab, Aldesleukin
- Where
- 12 sites in United States, Australia
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Completed, with results posted
All 77ALS (Amyotrophic Lateral Sclerosis)
T-regulatory Cells in ALS
This study is a randomized, placebo-controlled, phase 2a trial to study the biological activity, safety, and tolerability of regulatory T Lymphocytes (Tregs) taken and expanded outside of the body and returned back to the same…
- Trial name
- Tregs in ALS (NCT04055623)
- Testing
- Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- The Methodist Hospital Research Institute
Neuroblastoma
Therapy for Children With Advanced Stage Neuroblastoma
Neuroblastoma is the most common extracranial solid tumor in childhood, with nearly 50% of patients presenting with widespread metastatic disease.
- Trial name
- NCT01857934
- Testing
- cyclophosphamide, topotecan, hu14.18K322A
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- St. Jude Children's Research Hospital
Kidney Cancer
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
The main purpose of this study is to evaluate the effects of the interleukin-2 given in combination with pembrolizumab. Interleukin-2 (IL-2) is also called aldesleukin, or Proleukin™.
- Trial name
- NCT02964078
- Testing
- Pembrolizumab, Interleukin-2
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
High Risk Neuroblastoma
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
This phase III trial is studying the side effects of giving monoclonal antibody Ch14.18 together with sargramostim, aldesleukin, and isotretinoin after autologous stem cell transplant in treating patients with neuroblastoma.
- Trial name
- NCT01041638
- Testing
- Aldesleukin, Diagnostic Laboratory Biomarker Analysis, Dinutuximab
- Where
- 32 sites in United States
- Volunteers
- 105 people
- Sponsor
- National Cancer Institute (NCI)
Papillomavirus Infections, Cervical Intraepithelial Neoplasia
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have an HPV protein called E7 inside of their cells.
- Conditions
- Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms
- Trial name
- NCT02858310
- Testing
- E7 TCR cells, Aldesleukin, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Cancer Institute (NCI)